ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,303.27
0.12%
Dow Jones
40,003.59
0.34%
US Dollar vs MXN
16.6086
0.00%
Brent Oil
83.76
0.00%
Bitcoin
66,938.89
-0.21%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Reino Unido
  5. LSE
  6. Hutchison China Meditech Ltd (0J7G)

  7. Hutchison China Meditech Ltd (0J7G) Noticias

0J7G

Hutchison China Meditech (0J7G)

Hutchison China Meditech Ltd
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:LSE:0J7G
FechaHoraFuenteTítuloSímboloCompañía
11/01/202401:00RNS Non-RegulatoryHutchmed (China) Limited Sovleplenib NDA Granted Priority Review in ChinaLSE:0J7GHutchison China Meditech Ltd
29/12/202302:30UK RegulatoryHutchmed (China) Limited Total Voting RightsLSE:0J7GHutchison China Meditech Ltd
29/12/202302:30UK RegulatoryHutchmed (China) Limited Blocklisting Six Monthly ReturnLSE:0J7GHutchison China Meditech Ltd
21/12/202304:00UK RegulatoryHutchmed (China) Limited Overseas Regulatory AnnouncementLSE:0J7GHutchison China Meditech Ltd
13/12/202301:00RNS Non-RegulatoryHutchmed (China) Limited Completed Enrollment of Phase II/III TrialLSE:0J7GHutchison China Meditech Ltd
13/12/202301:00RNS Non-RegulatoryHutchmed (China) Limited Inclusion in National Reimbursement Drug ListLSE:0J7GHutchison China Meditech Ltd
01/12/202301:00RNS Non-RegulatoryHutchmed (China) Limited Clinical Data to be Presented at CongressesLSE:0J7GHutchison China Meditech Ltd
09/11/202301:00UK RegulatoryHutchmed (China) Limited U.S. FDA Approval of FRUZAQLA(TM) (fruquintinib)LSE:0J7GHutchison China Meditech Ltd
24/10/202303:30UK RegulatoryHutchmed (China) Limited Vesting of awards under the LTIPLSE:0J7GHutchison China Meditech Ltd
16/10/202303:30RNS Non-RegulatoryHutchmed (China) Limited Clinical Data to be Presented at ESMO 2023LSE:0J7GHutchison China Meditech Ltd
29/09/202303:30RNS Non-RegulatoryHutchmed (China) Limited NDA Submission for Fruquintinib in JapanLSE:0J7GHutchison China Meditech Ltd
14/09/202303:30UK RegulatoryHutchmed (China) Limited Director's Share DealingLSE:0J7GHutchison China Meditech Ltd
12/09/202303:30RNS Non-RegulatoryHutchmed (China) Limited Phase IIIb Savolitinib Results at WCLC 2023LSE:0J7GHutchison China Meditech Ltd
12/09/202301:00RNS Non-RegulatoryHutchmed (China) Limited Patient Enrollment Completed for Bridging StudyLSE:0J7GHutchison China Meditech Ltd
29/08/202301:00RNS Non-RegulatoryHutchmed (China) Limited BTD in China for Savolitinib for Gastric CancerLSE:0J7GHutchison China Meditech Ltd
21/08/202301:00UK RegulatoryHutchmed (China) Limited Sovleplenib Phase 3 Study Meets Primary EndpointLSE:0J7GHutchison China Meditech Ltd
07/08/202303:30UK RegulatoryHutchmed (China) Limited Exercise of Share Options by a DirectorLSE:0J7GHutchison China Meditech Ltd
31/07/202306:00UK RegulatoryHutchmed (China) Limited Interim Results and Business UpdatesLSE:0J7GHutchison China Meditech Ltd
20/07/202301:00RNS Non-RegulatoryHutchmed (China) Limited Breakthrough Therapy Designation for FruquintinibLSE:0J7GHutchison China Meditech Ltd
13/07/202303:30UK RegulatoryHutchmed (China) Limited Changes to Board and Technical CommitteeLSE:0J7GHutchison China Meditech Ltd
10/07/202301:00RNS Non-RegulatoryHutchmed (China) Limited Phase 1 Study of HMPL-415 InitiatedLSE:0J7GHutchison China Meditech Ltd
26/06/202303:30UK RegulatoryHutchmed (China) Limited HUTCHMED to Announce 2023 Half-Year ResultsLSE:0J7GHutchison China Meditech Ltd
16/06/202301:00UK RegulatoryHutchmed (China) Limited Phase III FRESCO-2 Results in The LancetLSE:0J7GHutchison China Meditech Ltd
15/06/202309:39UK RegulatoryHutchmed (China) Limited MAA of Fruquintinib Validated by the EMALSE:0J7GHutchison China Meditech Ltd
09/06/202304:30RNS Non-RegulatoryHutchmed (China) Limited HUTCHMED Highlights Presentations at EHA and ICMLLSE:0J7GHutchison China Meditech Ltd
06/06/202304:00UK RegulatoryHutchmed (China) Limited LTIP and Share Option SchemeLSE:0J7GHutchison China Meditech Ltd
26/05/202301:00UK RegulatoryHutchmed (China) Limited Fruquintinib NDA Granted Priority Review by FDALSE:0J7GHutchison China Meditech Ltd
26/05/202301:00RNS Non-RegulatoryHutchmed (China) Limited HUTCHMED Highlights Presentations at ASCO 2023LSE:0J7GHutchison China Meditech Ltd
17/05/202303:30UK RegulatoryHutchmed (China) Limited Standard form for notification of major holdingsLSE:0J7GHutchison China Meditech Ltd
12/05/202307:15UK RegulatoryHutchmed (China) Limited Annual General Meeting Poll ResultsLSE:0J7GHutchison China Meditech Ltd
 Showing the most relevant articles for your search:LSE:0J7G

Su Consulta Reciente

NASDAQ
FMBGX
Fidelity Advisor Municip...
BINA
OCEANUSDT
Ocean Protocol
BIT
S27839
Societe Generale Effekten
USOTC
BMQWF
BMO Equal Weight REITS (CE)
EU
SGSDH
Societe Generale SFH 0.4...
BIT
F36487
Vontobel Financial Produ...
BITMOT
605742
Oat Ot25 Eur 6
BIT
UR9ZP6
UniCredit Bank
EU
P652S
P652S
LSE
96IK
Int.fin. 27
LSE
EGMW
Is Wld Esg Acc
BIT
GRN
Green Oleo
BMF
DI1J29
DI1J29 - Abril 2029
ASX
LDX
Lumos Diagnostics
NASDAQ
ASDOX
Short Duration Fund G Cl...
LSE
BO11
Permanent .73
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados